| Short Description : | Mouse monoclonal Recombinant-HHV-8 antibody for use in IHC-P in human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications: | IHC-P |
| Host: | Mouse |
| Reactivity: | Human |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Clonality : | Monoclonal |
| Clone ID : | LN53 |
| Isotype: | IgG2ck |
| Conjugation: | Unconjugated |
| Purification: | Affinity purified |
| Dilution Range: | 1:100-200 |
| Formulation: | Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin |
| Storage Instruction: | Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C. |
| Immunogen: | Protein corresponding to the latent nuclear antigen 1 molecule of HHV-8 |
| Specificity: | Positive Control: Kaposi's sarcoma |
| Background | Zeta HHV8 Antibody. Zeta s recombinant mouse antibody recognizes HHV8, which encodes a latent nuclear antigen (LNA) , which is the product of the viral gene orf 73. LNA is capable of forming a complex with retinoblastoma susceptibility gene product, which may be related to its oncogenic activity. HHV8 is associated with three different diseases observed in AIDS patients: Kaposi s sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman s disease. HHV8 is the likely etiological agent of Kaposi s sarcoma. Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation. |
Information sourced from Uniprot.org

